Genpact Limited (35G) — Free Cash Flow Generation Index

Latest as of September 2025: 0.94x

Genpact Limited (35G) has a Free Cash Flow Generation Index of 0.94x as of September 2025. Free cash flow of €288.88 Million represents 1% of operating cash flow (€308.36 Million). Explore 35G capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.94x
Free Cash Flow / Operating CF

Free Cash Flow

€288.88 Million
EUR

Operating Cash Flow

€308.36 Million
EUR

Capital Expenditures

€19.48 Million
EUR

Genpact Limited Free Cash Flow Generation Index (2013–2024)

Historical FCF Generation Index trend for Genpact Limited across 12 annual periods. For the full cash flow conversion analysis, see Genpact Limited cash flow conversion.

Annual Free Cash Flow Generation for Genpact Limited (2013–2024)

Year-by-year Free Cash Flow Generation Index for Genpact Limited. Check 35G cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (EUR) Operating CF Capital Expenditures YoY Change
2024 0.86x €530.19 Million €615.42 Million €85.23 Million ▼ -3.6%
2023 0.89x €472.53 Million €528.53 Million €56.00 Million ▲ +1.9%
2022 0.88x €389.28 Million €443.67 Million €50.61 Million ▼ -4.4%
2021 0.92x €637.03 Million €694.28 Million €53.34 Million ▲ +6.4%
2020 0.86x €503.94 Million €584.31 Million €70.17 Million ▲ +15.6%
2019 0.75x €319.13 Million €427.89 Million €74.93 Million ▲ +41.4%
2018 0.53x €179.09 Million €339.51 Million €84.98 Million ▼ -33.6%
2017 0.79x €285.41 Million €359.08 Million €57.23 Million ▼ -36.8%
2016 1.26x €434.54 Million €345.77 Million €88.77 Million ▲ +5.6%
2015 1.19x €389.61 Million €327.44 Million €62.17 Million ▼ -3.3%
2014 1.23x €334.42 Million €271.84 Million €62.58 Million ▲ +6.3%
2013 1.16x €360.48 Million €311.60 Million €48.88 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).